Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Children (Basel) ; 11(4)2024 Apr 09.
Article in English | MEDLINE | ID: mdl-38671669

ABSTRACT

BACKGROUND: Thrombocytopenia is a prevalent presentation in childhood with a broad spectrum of etiologies, associated findings, and clinical outcomes. Establishing the cause of thrombocytopenia and its proper management have obvious clinical repercussions but may be challenging. This article provides an adaptation of the high-quality Clinical Practice Guidelines (CPGs) of pediatric thrombocytopenia management to suit Egypt's health care context. METHODS: The Adapted ADAPTE methodology was used to identify the high-quality CPGs published between 2010 and 2020. An expert panel screened, assessed and reviewed the CPGs and formulated the adapted consensus recommendations based on the best available evidence. DISCUSSION: The final CPG document provides consensus recommendations and implementation tools on the management of isolated thrombocytopenia in children and adolescents in Egypt. There is a scarcity of evidence to support recommendations for various management protocols. In general, complete clinical assessment, full blood count, and expert analysis of the peripheral blood smear are indicated at initial diagnosis to confirm a bleeding disorder, exclude secondary causes of thrombocytopenia and choose the type of work up required. The International Society of Hemostasis and thrombosis-Bleeding assessment tool (ISTH-SCC BAT) could be used for initial screening of bleeding manifestations. The diagnosis of immune thrombocytopenic purpura (ITP) is based principally on the exclusion of other causes of isolated thrombocytopenia. Future research should report the outcome of this adapted guideline and include cost-analysis evaluations.

2.
Ann Hematol ; 103(4): 1373-1388, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38388746

ABSTRACT

Pediatric transfusion is a complex area of medicine covering a wide age range, from neonates to young adults. Compared to adult practice, there is a relative lack of high-quality research to inform evidence-based guidelines. We aimed to adapt the pre-existing high-quality practice guidelines for the transfusion of blood components in different pediatric age groups to be available for national use by general practitioners, pediatricians, and other health care professionals. The guideline panel included 17 key leaders from different Egyptian institutions. The panel used the Adapted ADAPTE methodology. The panel prioritized the health questions and recommendations according to their importance for clinicians and patients. The procedure included searching for existing guidelines, quality appraisal, and adaptation of the recommendations to the target context of use. The guideline covered all important aspects of the indications, dosing, and administration of packed red cells, platelets, and fresh frozen plasma. It also included transfusion in special situations, e.g., chronic hemolytic anemia and aplastic anemia, management of massive blood loss, malignancies, surgery, recommendations for safe transfusion practices, and recommendations for modifications of cellular blood components. The final version of the adapted clinical practice guideline (CPG) has been made after a thorough review by an external review panel and was guided by their official recommendations and modifications. A set of implementation tools included algorithms, tables, and flow charts to aid decision-making in practice. This adapted guideline serves as a tool for safe transfusion practices in different pediatric age groups.


Subject(s)
Blood Component Transfusion , Evidence-Based Medicine , Adolescent , Child , Child, Preschool , Humans , Infant , Infant, Newborn , Young Adult , Blood Transfusion , Egypt , Evidence-Based Medicine/methods , Hemorrhage
3.
Echocardiography ; 33(7): 1114, 2016 07.
Article in English | MEDLINE | ID: mdl-27145064
4.
Echocardiography ; 33(1): 82-9, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26059008

ABSTRACT

BACKGROUND: Increased interest is focused on the long-term adverse effects of bone marrow transplantation. Subclinical cardiac involvement appears common in adults, but only a few reports have examined pediatric patients. MATERIALS AND METHODS: A prospective case-control study of 19 children with normal cardiac function undergoing autologous hematopoietic stem cell transplantation (HSCT) was performed. Tissue Doppler imaging (TDI) and echocardiographic measurements were obtained according to the guidelines of the American Society of Echocardiography before and 3 months after HSCT. RESULTS: Lateral mitral annulus before HSCT showed significant reduced mitral systolic annular velocity (P < 0.0001), early diastolic annular velocity (P < 0.0001), late diastolic annular velocity (P = 0.02) and prolonged isovolumetric relaxation time (IRT) (P < 0.0001) compared with control. Significant reduced mitral systolic annular velocity (P < 0.0001), early diastolic annular velocity (P = 0.0005) and Em/Am ratio (P = 0.004), with higher late diastolic annular velocity (P = 0.02) and prolonged isovolumetric contraction time (ICT) (P = 0.003) and IRT (P = 0.002) after HSCT, were observed. Investigation of lateral tricuspid annulus showed nearly similar results as the lateral mitral annulus. LV and RV Tei indices were higher before HSCT compared with control and remained high after HSCT. CONCLUSION: TDI detected subtle abnormalities in systolic and diastolic functions before and after HSCT, which suggests that a conditioning regimen may affect cardiac function.


Subject(s)
Echocardiography, Doppler , Heart/physiopathology , Peripheral Blood Stem Cell Transplantation , Adolescent , Blood Flow Velocity/physiology , Case-Control Studies , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Male , Mitral Valve/diagnostic imaging , Mitral Valve/physiopathology , Prospective Studies , Treatment Outcome , Ventricular Dysfunction, Left/diagnostic imaging , Ventricular Dysfunction, Left/physiopathology , Ventricular Dysfunction, Right/diagnostic imaging , Ventricular Dysfunction, Right/physiopathology
5.
Am J Blood Res ; 4(1): 1-6, 2014.
Article in English | MEDLINE | ID: mdl-25232499

ABSTRACT

The success that has been made in the care of patients with thalassemia has led to the emergence of unrecognized complications including several renal abnormalities. Chronic anemia and iron overload as well as the use of iron chelator are believed to lie behind these abnormalities. Many investigators document the presence of tubular dysfunction and abnormalities in glomerular filtration rate in these patients. In this review we will discuss the updates in the diagnosis, pathogenesis and prevention of renal complications of thalassemia.

6.
Med Oncol ; 30(2): 559, 2013.
Article in English | MEDLINE | ID: mdl-23553276

ABSTRACT

Children with acute leukemia are at high risk of hepatitis C infection, either by immunosuppression secondary to chemotherapy or by multiple transfusions of blood products during the course of the disease. Hepatitis C virus (HCV) infection constitutes a major problem during management of acute leukemia due to resultant portal hypertension or bleeding esophageal varices. Chronic HCV infection is a major cause of liver cirrhosis and hepatocellular carcinoma in leukemic survivors. The effect of amlodipine treatment on children with acute lymphoblastic leukemia (ALL) having portal hypertension secondary to HCV infection during maintenance chemotherapy has been studied. Sixty male children (mean age 11.83 ± 1.1 years) with ALL in remission and have HCV infection were included. Diagnosis of HCV infection was confirmed by real-time PCR. Thirty patients received 5 mg amlodipine orally per day for 4 weeks and compared to another 30 patients received placebo therapy and 30 age- and sex-matched children as a control group. Amlodipine significantly reduced the elevated portal blood pressure to normal level in doses which did not interfere with mechanism of action of chemotherapy (p ≤ 0.001). Treatment with amlodipine can be used to control portal hypertension in leukemic children having HCV-induced portal hypertension. HCV in leukemics could be virtually eliminated by proper testing of the blood transfusion pool.


Subject(s)
Amlodipine/administration & dosage , Calcium Channel Blockers/administration & dosage , Hepatitis C/physiopathology , Hypertension, Portal/drug therapy , Hypertension, Portal/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Administration, Oral , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Blood Pressure/drug effects , Child , Cohort Studies , Heart Rate/drug effects , Humans , Hypertension, Portal/virology , Male , Mercaptopurine/administration & dosage , Methotrexate/administration & dosage , Portal Pressure/drug effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/physiopathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/virology , Vincristine/administration & dosage
7.
J Exp Ther Oncol ; 10(2): 135-7, 2012.
Article in English | MEDLINE | ID: mdl-23350353

ABSTRACT

OBJECTIVES: To present our single institution experience with 10 cases of embryonal rhabdomyosarcoma diagnosed over 5 years. METHODS: Retrospective analysis of the medical records of 10 patients. The initial presenting data as age, complains and staging were analyzed. Surgical interference of all cases was studied. The follow up data regarding survival and recurrences were analyzed. RESULTS: The mean age at diagnosis was 4.3 years (range: 2-12). Six cases (60%) were subjected to "True Cut" biopsy and 4 cases (40%) were subjected to complete surgical excision of the tumor. All cases received chemotherapy. "Vincristine, Actinomycin D, Cyclophosphamide" combination was the most commonly used. Radiation therapy was used in 3 patients (30%) in the form of external beam radiation. The 5-year overall survival of our studied cases were 80%. CONCLUSION: The recurrence rate of our retrospectively studied 10 cases of embryonal rhabdomyosarcoma of vagina and cervix was high (70%). However, five-year survival was 80%. Combined modality treatment is essential to improve prognosis.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Rhabdomyosarcoma, Embryonal/mortality , Uterine Cervical Neoplasms/mortality , Child , Child, Preschool , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Dactinomycin/administration & dosage , Female , Follow-Up Studies , Humans , Medical Records , Prognosis , Radiotherapy Dosage , Retrospective Studies , Rhabdomyosarcoma, Embryonal/therapy , Survival Rate , Time Factors , Uterine Cervical Neoplasms/therapy , Vincristine/administration & dosage
8.
Pediatr Blood Cancer ; 56(2): 202-5, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21157889

ABSTRACT

BACKGROUND: Neuroblastoma is the second most common extracranial malignant tumor of childhood and the most common solid tumor of infancy which is characterized by bone metastasis. Previous reports on bone mineral density (BMD) in patients with leukemia and solid malignancies concentrate on long-term survivors and on the effect of chemotherapeutic agents and irradiation. Also, evaluation of BMD in neuroblastoma was reported in few studies which were conducted upon adult survivors of childhood cancer. Previous studies on both acute leukemia and lymphoma patients suggested that the disease process itself played a role in decrease BMD. METHODS: We evaluated 27 patients with newly diagnosed neuroblastoma for both lumbar (L2-L4) BMD and total BMD using dual energy X-ray absorptiometery (DXA) scan to highlight the effect of neuroblastoma as a disease process on BMD as this disease characterized by bone metastasis. RESULTS: Three out of the 27 patients showed low bone mass in both lumbar and total BMD studies. CONCLUSION: Low bone mass may occur in early disease process of neuroblastoma and it is important to consider BMD assessment during the early course of the disease as well as the long-term survivors as a part of the patient screening in suspected cases.


Subject(s)
Bone Density , Bone Diseases, Metabolic/etiology , Bone Neoplasms/secondary , Nervous System Neoplasms/pathology , Neuroblastoma/secondary , Osteoporosis/etiology , Absorptiometry, Photon , Adolescent , Autonomic Nervous System Diseases/complications , Autonomic Nervous System Diseases/pathology , Bone Neoplasms/pathology , Child , Child, Preschool , Female , Humans , Infant , Male , Nervous System Neoplasms/complications
9.
World J Pediatr ; 7(1): 60-4, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20549409

ABSTRACT

BACKGROUND: pediatric hematology/oncology patients are faced with an increased risk of nosocomial infections (NIs) that vary in different populations and different institutions with considerable morbidity and mortality. This study was undertaken to assess the frequency and patterns of NIs in 1564 pediatric patients and to determine the prevalence of causative organisms and their antimicrobial sensitivity. METHODS: a retrospective analysis was made in the patients admitted between January 2007 and January 2008 to the pediatric hematoloy/oncology unit of Mansoura University, Egypt. The 1564 patients showed 2084 admissions and 27 092 inpatient days. The Centers for Disease Control and Prevention criteria were used as a standard definition for NI. RESULTS: the overall rate of NIs in all patients and neutropenic patients was 8.6 and 25.3 per 1000 patient-days respectively. The frequent sites of NIs were blood stream (42.7%), the respiratory system (25.3%), the urinary system (22.2%) and the central nervous system (9.8%), whereas nosocomial fever of unknown origin constituted 52.9% of cases. The incidence of NIs was significantly higher during neutropenic days (P<0.001). Gram-positive organisms represented 64.5% of pathogens (Staphylococci 71.5%, Streptococci 16%, and pneumococci 7%), and Gram-negative organisms represented 30% (E. coli 48.6%, Klebsiella 15.7%, Pseudomonas 35.7%, and C. albicans 5.5%). Positive cultures were more frequent in summer (July to September). Susceptibility of isolated organisms was relatively low (cefoperazone/sulbactam 49.9%, amikacin 35.9%, imipenem/cilastin 34.4%, cefoperazone 33.6%, and vancomycin 36.5%). Methicillin-resistant S. aureus, extended spectrum beta lactamase and vancomycin resistant enterococci represented 30%, 45% and 75% of isolated S. aureus, Gram-negative organisms and Enterococci, respectively. CONCLUSIONS: blood stream infection and fever of unknown origin are the most common nosocomial infections in pediatric hematology/oncology patients with a higher risk during neutropenic days. Isolated organisms are multi-drug resistant, predominantly Gram-positive pathogens with a high incidence of methicillin-resistant S. aureus, extended spectrum beta lactamase and vancomycin resistant enterococci organisms.


Subject(s)
Cancer Care Facilities/statistics & numerical data , Cross Infection/epidemiology , Fever of Unknown Origin/epidemiology , Gram-Negative Bacterial Infections/epidemiology , Gram-Positive Bacterial Infections/epidemiology , Hospitals, Pediatric/statistics & numerical data , Child , Cross Infection/diagnosis , Cross Infection/microbiology , Egypt/epidemiology , Fever of Unknown Origin/diagnosis , Fever of Unknown Origin/microbiology , Gram-Negative Bacterial Infections/complications , Gram-Negative Bacterial Infections/diagnosis , Gram-Positive Bacterial Infections/complications , Gram-Positive Bacterial Infections/diagnosis , Hospital Units/statistics & numerical data , Hospitals, University/statistics & numerical data , Humans , Incidence , Infection Control/methods , Length of Stay/statistics & numerical data , Population Surveillance , Retrospective Studies , Risk Assessment , Risk Factors
10.
Leuk Lymphoma ; 51(4): 656-63, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20218813

ABSTRACT

We aimed for the comparison of two protocols (OAP and COMP) as chemotherapy treatment in children with Hodgkin lymphoma (HL). A total of 119 children newly diagnosed with HD were divided to receive either the anthracycline-based OAP protocol or the alkylating-agent-based COMP protocol. Sixty patients received the OAP protocol and 59 patients received the COMP protocol. Complete response was achieved for 81.4% of patients treated with the COMP protocol versus 53.3% for those who received the OAP treatment. Toxic hepatitis or liver cell failure was recorded in 5% of patients treated with the COMP protocol. Complications were more frequent in those treated with the OAP protocol, as 6.8% developed heart failure and 20% showed toxic hepatitis or liver cell failure. The relapse rate was almost equal in both treatment arms. Patients treated with the COMP protocol achieved a better response and less toxicity but with similar survival to those given the OAP protocol.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Hodgkin Disease/drug therapy , Mechlorethamine/administration & dosage , Procarbazine/administration & dosage , Adolescent , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Child , Child, Preschool , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Cytarabine/administration & dosage , Cytarabine/adverse effects , Egypt , Female , Follow-Up Studies , Hodgkin Disease/mortality , Humans , Infant , Male , Mechlorethamine/adverse effects , Methotrexate/administration & dosage , Methotrexate/adverse effects , Prednisone/administration & dosage , Prednisone/adverse effects , Procarbazine/adverse effects , Survival Analysis , Vincristine/administration & dosage , Vincristine/adverse effects
11.
Adv Hematol ; 2009: 689639, 2009.
Article in English | MEDLINE | ID: mdl-19960046

ABSTRACT

Although cancer therapies have experienced great success nowadays, yet the associated toxic response and free radicals formation have resulted in significant number of treatment-induced deaths rather than disease-induced fatalities. Complications of chemotherapy have forced physicians to study antioxidant use as adjunctive treatment in cancer. This study aimed to evaluate the antioxidant role of vitamin E and N-acetyl cysteine (NAC) in overcoming treatment-induced toxicity in acute lymphoblastic leukaemia (ALL) during the intensive period of chemo-/radiotherapy, almost the first two months of treatment. Forty children newly diagnosed with ALL were enrolled in this study. Twenty children (group I) have taken vitamin E and NAC supplementations with chemotherapy and the other twenty children (group II) have not taken any adjuvant antioxidant therapy. They were evaluated clinically for the occurrence of complications and by the laboratory parameters (blood levels of glutathione peroxidase (Glu.PX) antioxidant enzyme, malondialdehyde (MDA), tumor necrosis factor-alpha (TNF-alpha), liver enzymes, and bone marrow picture). Results revealed reduced chemotherapy and radiotherapy toxicity as evidenced by decreasing level of MDA, increasing level of Glu.Px and decreased occurrence of toxic hepatitis, haematological complications, and need for blood and platelet transfusions in group I compared to group II. We can conclude that vitamin E and NAC have been shown to be effective as antioxidant adjuvant therapy in children with ALL to reduce chemo-/radiotherapy-related toxicities during the initial period of treatment.

12.
Hematology ; 14(6): 335-40, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19941740

ABSTRACT

AIM: Determination of frequency and prognostic significance of murine double minute protein-2 (MDM-2) over expression and its association with p53 status in children with acute lymphoblastic leukemia (ALL). METHODS: MDM-2 expression by flow cytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of 46 ALL children (at initial diagnosis) and control group. RESULTS: MDM-2 was significantly overexpressed in 15 patients (32.6%). p53 mutation was detected in six out of 46 patients at initial diagnosis, three of them were out of 29 cases achieving complete remission (CR) and the other three cases were out of 17 of relapsed patients, which is significantly higher than CR group (P<0.05). Positive correlation was found between the MDM-2 overexpression and initial WBCs count, peripheral blast cell count and presence of CNS blasts (P<0.05, <0.05 and <0.05 respectively). CONCLUSION: MDM-2 is overexpressed in a significant number of childhood ALL, and more often observed in the poor outcome group and its frequency is not related to p53 status. Measurement of MDM-2 as a bad prognostic marker even in cases with non-mutant p53 is very important. Moreover, MDM-2 may be a potential molecular target for production of new cancer therapy.


Subject(s)
Biomarkers, Tumor/biosynthesis , Blast Crisis/genetics , Blast Crisis/metabolism , Gene Expression Regulation, Leukemic , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Proto-Oncogene Proteins c-mdm2/biosynthesis , Tumor Suppressor Protein p53/genetics , Adolescent , Biomarkers, Tumor/genetics , Blast Crisis/diagnosis , Blast Crisis/pathology , Blast Crisis/therapy , Child , Child, Preschool , Female , Flow Cytometry , Humans , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Prognosis , Proto-Oncogene Proteins c-mdm2/genetics , Recurrence , Remission Induction , Tumor Suppressor Protein p53/metabolism
13.
Hematology ; 14(5): 271-6, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19843382

ABSTRACT

Histiocytosis disorders include a wide group of disorders characterized by monocytes, macrophages and dendritic cell infiltration of different tissues. There are few clinico-epidemiologic studies of such disease. Our study was designed to look at the clinico-epidemiological features and outcome of patients with histiocytosis disorders in Northeast Egypt. Twenty-seven cases with histiocytosis disorders accrued over a 5-year period were analyzed and classified as having unifocal, multifocal, or multisystem disease. They were 14 males and 13 females. Twenty-two patients representing 81.5% of cases were more than two years of age while 5 patients (18.5%) were less than 2 years. Lymphadenopathy was the commonest presentation (55.55%) followed by bone lesions (44.44%). Involvement was unifocal in 12, multifocal in 10, and multisystem in 5 cases. The histological features were relatively uniform regardless of the clinical severity, and consisted of Langerhans cells, eosinophils, histiocytes, plasma cells, giant cells and fibrosis. The treatment consisted of a combination of surgery, chemotherapy, and/or radiotherapy. Lymphadenopathy was the most common clinical presentation in our locality. Response to treatment was poor in patients with multisystem disease. Patients with age less than 2 years were more likely to have increased risk of morbidity and mortality, due to widespread disease.


Subject(s)
Histiocytosis/mortality , Age Factors , Child , Child, Preschool , Egypt/epidemiology , Female , Giant Cells/pathology , Giant Cells/physiology , Histiocytosis/pathology , Histiocytosis/therapy , Humans , Infant , Langerhans Cells/pathology , Leukocytes/pathology , Longitudinal Studies , Male , Survival Rate
14.
World J Pediatr ; 5(3): 229-31, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19693470

ABSTRACT

BACKGROUND: Thyroid cancer is rare in children especially before the age of 10 years. Upper airway obstruction and pulmonary infiltration are rare manifestations of such tumor. METHODS: An 8-year-old school girl was admitted to Mansoura University Children's Hospital for a papillary thyroid carcinoma manifested by severe upper respiratory tract obstruction. CT scan of the chest revealed multiple miliary shadows in both lungs. RESULTS: Total thyroidectomy was performed and pathological examination confirmed the diagnosis of papillary carcinoma of the thyroid gland. The patient received ablative dose of Iodine 131 and replacement therapy of L-thyroxine. CONCLUSION: Thyroid cancer, although rare, should be considered for differential diagnosis of upper airway obstruction and pulmonary metastases.


Subject(s)
Airway Obstruction/etiology , Carcinoma, Papillary/complications , Carcinoma, Papillary/diagnosis , Thyroid Neoplasms/complications , Thyroid Neoplasms/diagnosis , Carcinoma, Papillary/pathology , Carcinoma, Papillary/surgery , Child , Female , Humans , Lung Neoplasms/secondary , Thyroid Neoplasms/pathology , Thyroid Neoplasms/surgery , Thyroidectomy
15.
J Pediatr Hematol Oncol ; 31(3): 173-6, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19262242

ABSTRACT

BACKGROUND: Oncology patients are at particular risk for parvovirus B19 infection, which may cause severe, persistent, usually nonspecific illness in this group. AIM: This study was designed to assess the prevalence and impact of parvovirus B19 in pediatric oncology patients receiving chemotherapy, and to define the optimal diagnostic tests in such patients. SUBJECTS AND METHODS: Fifty-nine children under chemotherapy (39 with acute lymphocytic leukemia and 20 with solid tumors) with mean age of 4.96+/-1.94 years, in addition to 30 healthy children of matched age and sex, were enrolled in this study. Clinical and laboratory data were collected by examination and from patients' records. Specific parvovirus B19 immunoglobulin (Ig) M and IgG antibodies were assessed by enzyme-linked immunosorbent assay, and parvovirus DNA was detected by nested polymerase chain reaction (PCR) for all patients and controls. RESULTS: Parvovirus DNA was detected in 16 (27.1%), IgM in 3 (5.1%), and IgG in 36 (61%) patients. IgM had sensitivity, specificity, and accuracy of 18.75%, 100%, and 77.9%, respectively, whereas those of IgG were 81.25%, 53.4%, and 61%, respectively. PCR-positive patients had significantly higher frequency of unexplained anemia, red blood cell transfusions, and longer hospital stay than PCR-negative patients (P<0.001). Multiple linear regression analysis showed that unexplained anemia and multiple red blood cell transfusions were the most important variables that can predict PCR positivity. CONCLUSIONS: Parvovirus B19 is not an uncommon problem in pediatric oncology patients who exhibited weak antibody response and nonspecific clinical features. Screening of these patients with PCR rather than serology is recommended when infection is suspected.


Subject(s)
DNA, Viral/analysis , Immunocompromised Host , Parvoviridae Infections/blood , Parvoviridae Infections/diagnosis , Parvoviridae Infections/immunology , Polymerase Chain Reaction , Antibodies, Viral/blood , Antineoplastic Agents/therapeutic use , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Neoplasms/drug therapy , Parvovirus B19, Human/genetics , Prevalence , Sensitivity and Specificity
17.
Egypt J Immunol ; 15(1): 93-100, 2008.
Article in English | MEDLINE | ID: mdl-20306673

ABSTRACT

The murine double minute protein-2 (MDM-2) oncogene is a determinant of embryogenesis, tumorigenesis, and cell cycle progression. The effects of MDM-2 on these processes depend, in part, on its ability to inactivate the p53 tumor suppressor gene. Our goal was to determine whether MDM-2 protein overexpressions or p53 gene mutations are a frequent event in poor outcome pediatric acute lymphoblastic leukemia (ALL). This work was conducted on 46 children with ALL (31 males and 15 females) with age range 2-18 years, 18 children with matched age and sex were enrolled in the study as a control group. The MDM-2 expression by flowcytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of ALL children (at initial diagnosis) and also of control group. The ALL children were treated by the modified BFM 76179 protocol of therapy, 29 patients (63%) achieved complete remission, while 17 patients (37%) were subsequently failed to achieve complete remission or relapsed within 6 months of achieving complete remission (CR). MDM-2 was significantly overexpressed in 15 ALL patients (32.6%), compared to that of healthy controls, 4 of them (4/15), were out of 29 cases of CR (13.8%), and the other 11 cases were out of 17 relapsed cases (64.7%). In contrast to overexpression of MDM-2, the mutation of p53 was detected in 6 (13%) out of 46 ALL patients at the initial time of diagnosis, 3 of them (10.3%) were out of 29 cases of CR and the other 3 cases (17.6%) were out of 17 of relapsed group, which is significantly higher than CR group (P < 0.05). In relapsed group, 2 patients out of 3 cases with p53 mutation were MDM-2 negative, also, all 3 cases of mutant P53 among patients in CR were negative MDM2. A positive correlation was found between the MDM-2 overexpression and initial WBCs count, blast cell counts in peripheral blood and presence of CNS blasts (p < 0.05, p < 0.05 and p < 0.05 respectively). These results indicate that MDM-2 is overexpressed in a significant number of childhood ALL, it is more frequent in relapsed cases and its frequency is not related to p53 status. Thus measuring of MDM-2 as a bad prognostic marker even in cases with non mutant P53 is very important. Moreover, MDM-2 may be a potential molecular target for production of new cancer therapy.


Subject(s)
Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Proto-Oncogene Proteins c-mdm2/metabolism , Tumor Suppressor Protein p53/genetics , Adolescent , Blood Cells/pathology , Bone Marrow Cells/metabolism , Bone Marrow Cells/pathology , Child , Child, Preschool , Female , Gene Expression/genetics , Hemoglobins/analysis , Humans , Leukocyte Count , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/pathology , Lymphocyte Count , Male , Platelet Count , Polymorphism, Single-Stranded Conformational/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Prognosis
18.
Pediatr Nephrol ; 18(6): 516-20, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12707837

ABSTRACT

Tumor necrosis factor-alpha (TNF-alpha) levels in supernatant fluid from cultured peripheral blood mononuclear cells (PBMC) were measured by ELISA in 54 children with active non-inherited forms of primary nephrotic syndrome (PNS), 10 nephrotics in remission, and 10 healthy controls. Children with active PNS included 21 patients with steroid-sensitive (SS) minimal change nephrotic syndrome (MCNS), 5 patients with steroid-resistant (SR) MCNS, 11 with SR focal segmental glomerulosclerosis (FSGS), 6 patients with SS diffuse mesangial proliferation (DMP), 5 patients with SR DMP, and 6 patients with mesangiocapillary glomerulonephritis (MCGN). Patients with active PNS had elevated TNF-alpha production compared with controls. Remission was associated with normalization of TNF-alpha production. There was a positive correlation between TNF-alpha production and the degree of proteinuria ( r=0.34, P=0.013), mesangial hypercellularity ( r=0.42, P=0.028), and glomerulosclerosis ( r=0.46, P=0.001). By using ROC curve, TNF-alpha production greater or equal to a cut-off point of 50 pg/ml could be used to predict resistance to steroid therapy (predictability 93.2%). By discriminate analysis, TNF-alpha production could be used to discriminate between patients with SR MCNS, SR FSGS, and SR DMP (predictability 100%). In conclusion, TNF-alpha from cultured PBMC might be involved in the pathogenesis of proteinuria as well as the pathological changes that occur in non-inherited forms of PNS. TNF-alpha levels in PBMC culture could be used to predict the pathological type of PNS and the response of these patients to steroid therapy.


Subject(s)
Leukocytes, Mononuclear/metabolism , Nephrotic Syndrome/diagnosis , Nephrotic Syndrome/immunology , Tumor Necrosis Factor-alpha/metabolism , Adolescent , Cells, Cultured , Child , Child, Preschool , Female , Humans , Infant , Leukocytes, Mononuclear/cytology , Male , Nephrotic Syndrome/metabolism , Predictive Value of Tests , Proteinuria/diagnosis , Proteinuria/immunology , Proteinuria/metabolism , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...